Get the Stockscreener App
5.47
6.42%
0.33
After Hours:
5.49
0.02
+0.37%
Q 32 Bio Inc stock is traded at $5.47, with a volume of 335.53K.
It is up +6.42% in the last 24 hours and down -3.01% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
See More
Previous Close:
$5.14
Open:
$5.1
24h Volume:
335.53K
Relative Volume:
1.18
Market Cap:
$92.75M
Revenue:
$53.74M
Net Income/Loss:
$33.24M
P/E Ratio:
1.7078
EPS:
3.203
Net Cash Flow:
$-33.54M
1W Performance:
-0.55%
1M Performance:
-3.01%
6M Performance:
+135.78%
1Y Performance:
+255.19%
1-Day Range:
$5.02
$5.52
1-Week Range:
$4.97
$5.70
52-Week Range:
$1.345
$8.045
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
5.47 | 87.16M | 53.74M | 33.24M | -33.54M | 3.203 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | H.C. Wainwright | Buy |
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Q32 Bio gears up to report Q1 earnings: What's in the cards? - MSN
Q32 Bio Inc. posts first quarter 2026 financial results and issues corporate update - Traders Union
Q32 Bio Inc. 1Q 2026: Net loss $(7.61M), EPS $(0.54) — 10-Q Summary - TradingView
Q32 Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Q32 Bio: Q1 Earnings Snapshot - KVUE
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards? - sharewise.com
Q32 Bio (QTTB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Q32 Bio (NASDAQ:QTTB) Trading Down 3.8%What's Next? - MarketBeat
Q32 Bio Expands ATM Offering With New $75M Prospectus - The Globe and Mail
QTTB Price Today: Q32 Bio Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Q32 Bio files prospectus for up to $75 million at-the-market share offering - Investing.com UK
Q32 Bio Inc files additional prospectus to offer up to $75 million of common stock - marketscreener.com
Q32 Bio files $75M prospectus supplement after exhausting $14.2M ATM offering - TradingView
Q32 Bio (QTTB) Stock: Momentum Outlook | Q32 Bio Inc. delivers 515.8% EPS surprise topping estimatesRisk Event - Cổng thông tin điện tử tỉnh Lào Cai
Momentum Outlook | Q32 Bio Inc. delivers 515.8% EPS surprise topping estimatesPro Level Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai
Q32 Bio (QTTB) Stock Insider Ownership (Bearish Sentiment) 2026-04-22Social Buy Zones - Xã Vĩnh Công
Q32 Bio (QTTB) Stock: Buy Decision Breakdown (Bullish Sentiment) 2026-04-20Blue Chip Stocks - Xã Vĩnh Công
Pullback Watch: Will Q32 Bio Inc benefit from geopolitical trendsStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Market Pulse: Will Q32 Bio Inc stock benefit from M A2026 PostEarnings & Stepwise Trade Signal Guides - baoquankhu1.vn
Is Q32 Bio (QTTB) Stock Trending Up | Price at $5.09, Down 6.95%Undervalued Stocks - Xã Thanh Hà
Q32 Bio Inc. schedules fireside chat at upcoming Needham healthcare conference - Traders Union
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference - Weekly Voice
Q32 Bio management goes live online April 15 at Needham conference - Stock Titan
Q32 Bio (NASDAQ:QTTB) Shares Up 4.6% – Should You Buy? - Defense World
Will Q32 Bio (QTTB) Stock Outperform Peers | Price at $5.83, Down 8.62%Trader Community Insights - Newser
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect? - Yahoo Finance
Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive (NASDAQ:QTTB) - Seeking Alpha
Q32 Bio Launches Flexible $14.2 Million ATM Program - The Globe and Mail
Q32 Bio enters $14.2 million at-the-market equity sales agreement with Cantor Fitzgerald - Investing.com
If You Invested $1,000 in Q32 BIO INC (QTTB) - stocktitan.net
Q32 Bio (QTTB) CSO granted 37,500 RSUs and updates holdings - Stock Titan
Q32 Bio (QTTB) awards 53,250 RSUs to its CFO and President - Stock Titan
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Best Momentum Stocks to Buy for March 19th - theglobeandmail.com
Q32 Bio (NASDAQ:QTTB) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
Best Momentum Stocks to Buy for March 13th - The Globe and Mail
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio, Inc. Experiences Comprehensive Evaluation Adjustment Amid Financial Landscape Changes - Markets Mojo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (ATRC), Q32 Bio (QTTB) and Shoulder Innovations, Inc. (SI) - The Globe and Mail
FY2026 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing - The Globe and Mail
What is HC Wainwright’s Forecast for Q32 Bio Q1 Earnings? - Defense World
Q1 Earnings Estimate for Q32 Bio Issued By HC Wainwright - MarketBeat
Q32 Bio Reports Q4 2025 Financial Results, Highlights SIGNAL-AA Trial Progress and Strong Financial Runway into 2027 - Minichart
Q 32 Bio Inc Stock (QTTB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):